Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET
Company Participants
Pete De Spain - Head, Investor Relations
Dr. Troy Wilson - President and CEO
Tom Doyle - Senior Vice President, Finance and Accounting
Dr. Mollie Leoni - Executive Vice President, Clinical Development
Conference Call Participants
Li Watsek - Cantor
Jonathan Chang - Leerink Partners
Jason Zemansky - Bank of America
Roger Song - Jefferies
Charles Zhu - LifeSci Capital
Phil Nadeau - TD Cowen
Peter Lawson - Barclays
Justin Zelin - BTIG
Brad Canino - Stifel
Operator
Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Also, today’s call is being recorded. [Operator Instructions]
Now at this time, I’ll turn things over to Mr. Pete De Spain, Head of Investor Relations. Please go ahead, sir.
Pete De Spain
Great. Thank you, Bo. Good afternoon. And welcome to Kura Oncology’s third quarter 2024 conference call. Joining me on the call are Dr. Troy Wilson, our President and Chief Executive Officer; and Tom Doyle, our Senior Vice President of Finance and Accounting; Dr.
Mollie Leoni, our Executive Vice President of Clinical Development, is also with us and available to answer questions.
Before I turn the call over to Dr. Wilson, I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Such statements represent management’s judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura’s filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.
With that, I’ll now turn the call over to Troy.
Dr. Troy Wilson
Thank you, Pete, and thank you all for joining us. We continue to generate what we believe is a robust clinical data package to support the broad development of our menin inhibitor program, beginning with ziftomenib. We believe ziftomenib is well positioned to transform the treatment of menin-dependent AML so that patients with cancer may lead better, longer lives.
Earlier this week, two abstracts reporting preliminary data from our KOMET-007 combination trial of ziftomenib were posted on the website of the American Society of Hematology. As of the June 21 data cutoff, the abstracts continue to support a potential best-in-class safety and tolerability profile for ziftomenib, as well as robust and durable activity in combination with standards-of-care, including venetoclax + azacitidine, as well as cytarabine + daunorubicin, commonly known as 7+3.